Key result
Cardiovascular trials show marked heterogeneity in kidney endpoints, with nearly 40% excluding advanced CKD.
Systematic Review (n=33)
Answers are grounded in this paper and cite their sources.
There is significant heterogeneity in the reporting and definitions of kidney function and outcomes in large T2DM, kidney, and HF trials, highlighting the need for standardized definitions to improve cross-trial comparability.
Heterogeneity in the reporting of kidney function, kidney outcomes, and definitions for kidney endpoints in clinical trials makes it challenging to compare results and gauge incremental benefit of interventions across trials. We conducted a systematic review of the ascertainment of baseline kidney variables, reporting of kidney endpoints, and definitions used to characterize these endpoints in type 2 diabetes mellitus (T2DM), kidney, and heart failure (HF) trials. Medline, Scopus, and ClinicalTrials.gov were searched from January 2014 through January 2021 for large (>1000 participants) T2DM, HF, and kidney disease trials and their secondary analyses. Trial publication and supplementary appendices were searched to abstract relevant data. Thirty-three trials (16 T2DM; 10 HF; 7 kidney diseases) were included. Thirteen trials did not include patients with estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2 and for trials that did, representation of this cohort ranged from 0.1% to 15%. Reporting of baseline kidney function and albuminuria remained low, especially in HF trials. Variability was observed in the definition of chronic kidney disease, sustained decline in eGFR, end-stage kidney disease, kidney death, and kidney composite endpoint across trials. eGFR slope was reported in less than half trials, with differences observed in statistical models, definition of acute or chronic slope, and follow-up duration across trials. Significant heterogeneity in reporting of kidney function and kidney outcomes in large T2DM, kidney, and HF trials underscores the need for future stakeholders to draft a consensus solution. Detailed profiling of patients at baseline, accrual of more patients with advanced kidney disease, and standardization of definitions in trials may improve the ability to compare the results across trials.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2021) conducted a systematic review in Type 2 diabetes mellitus, heart failure, and kidney disease (n=33). Clinical trial reporting practices was evaluated on Ascertainment of baseline kidney variables, reporting of kidney endpoints, and definitions. A systematic review of 33 large trials found significant heterogeneity in kidney endpoint definitions, with 13 trials excluding patients with eGFR <30 and others including only 0.1% to 15%.
Synapse has enriched 10 related papers. Consider them for comparative context: